170 related articles for article (PubMed ID: 23963146)
1. Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer.
Blencowe NS; Whistance RN; Strong S; Hotton EJ; Ganesh S; Roach H; Callaway M; Blazeby JM
Br J Cancer; 2013 Sep; 109(6):1445-50. PubMed ID: 23963146
[TBL] [Abstract][Full Text] [Related]
2. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
[TBL] [Abstract][Full Text] [Related]
3. State-of-the-art imaging in oesophago-gastric cancer.
Withey SJ; Goh V; Foley KG
Br J Radiol; 2022 Sep; 95(1137):20220410. PubMed ID: 35671095
[TBL] [Abstract][Full Text] [Related]
4. Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
Gillies RS; Middleton MR; Maynard ND; Bradley KM; Gleeson FV
Eur Radiol; 2011 Feb; 21(2):274-80. PubMed ID: 20821013
[TBL] [Abstract][Full Text] [Related]
5. Impact of incidental findings on integrated 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in patients with gastric cancer.
Tae CH; Lee JH; Choi JY; Min BH; Rhee PL; Kim JJ
Asia Pac J Clin Oncol; 2015 Mar; 11(1):34-40. PubMed ID: 25560093
[TBL] [Abstract][Full Text] [Related]
6. Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review.
Wong WL; Chambers RJ
Abdom Imaging; 2008; 33(2):183-90. PubMed ID: 17619927
[TBL] [Abstract][Full Text] [Related]
7. PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers.
Malibari N; Hickeson M; Lisbona R
PET Clin; 2015 Jul; 10(3):311-26. PubMed ID: 26099669
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography-computed tomography in oesophageal cancer staging: a tailored approach.
Bunting DM; Lai WW; Berrisford RG; Wheatley TJ; Drake B; Sanders G
World J Surg; 2015 Apr; 39(4):1000-7. PubMed ID: 25446482
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
You JJ; Wong RK; Darling G; Gulenchyn K; Urbain JL; Evans WK
J Thorac Oncol; 2013 Dec; 8(12):1563-9. PubMed ID: 24389439
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma.
Rankin SC; Taylor H; Cook GJ; Mason R
Clin Radiol; 1998 Sep; 53(9):659-65. PubMed ID: 9766719
[TBL] [Abstract][Full Text] [Related]
11. Incidental focal colonic lesions found on (18)Fluorodeoxyglucose positron emission tomography/computed tomography scan: further support for a national guideline on definitive management.
Farquharson AL; Chopra A; Ford A; Matthews S; Amin SN; De Noronha R
Colorectal Dis; 2012 Feb; 14(2):e56-63. PubMed ID: 21831171
[TBL] [Abstract][Full Text] [Related]
12. The Comparison of Computed Tomography Perfusion, Contrast-Enhanced Computed Tomography and Positron-Emission Tomography/Computed Tomography for the Detection of Primary Esophageal Carcinoma.
Genc B; Kantarci M; Sade R; Orsal E; Ogul H; Okur A; Aydin Y; Karaca L; Eroğlu A
Med Princ Pract; 2016; 25(3):254-9. PubMed ID: 26784024
[TBL] [Abstract][Full Text] [Related]
13. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
Ng SP; David S; Alamgeer M; Ganju V
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
[TBL] [Abstract][Full Text] [Related]
14. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
[TBL] [Abstract][Full Text] [Related]
15. Impact of FDG-PET for staging of oesophageal cancer.
Imdahl A; Hentschel M; Kleimaier M; Hopt UT; Brink I
Langenbecks Arch Surg; 2004 Aug; 389(4):283-8. PubMed ID: 15197549
[TBL] [Abstract][Full Text] [Related]
16. Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to
Zheng D; Liu Y; Liu J; Li K; Lin M; Schmidt H; Xu B; Tian J
Cancer Imaging; 2020 Jun; 20(1):39. PubMed ID: 32546207
[TBL] [Abstract][Full Text] [Related]
17. Routinely staging gastric cancer with
Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
[TBL] [Abstract][Full Text] [Related]
18. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
19. The decision to operate: role of integrated computed tomography positron emission tomography in staging oesophageal and oesophagogastric junction cancer by the multidisciplinary team.
Berrisford RG; Wong WL; Day D; Toy E; Napier M; Mitchell K; Wajed S
Eur J Cardiothorac Surg; 2008 Jun; 33(6):1112-6. PubMed ID: 18328726
[TBL] [Abstract][Full Text] [Related]
20. The value of [18F]fluorodeoxyglucose-PET/CT in oesophageal cancer.
Rankin S
Cancer Imaging; 2011 Oct; 11 Spec No A(1A):S156-60. PubMed ID: 22186083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]